Curcumin is one of the most successful compounds investigated in recent years, and is currently being assessed both for prevention and treatment of cancer.1 Curcumin can exist in at least two tautomeric forms, keto and enol. The enol form is more energetically stable in the solid phase as well as in solution. Curcumin incorporates several functional groups. The aromatic ring systems, which are polyphenols, are connected by two α-β-unsaturated carbonyl groups. The diketones form stable enols or, because they are easily deprotonated, form enolates, whereas the α-β-unsaturated carbonyl groups are a good Michael acceptor and undergoes nucleophilic addition. Most of the know activities of curcumin have been assigned to its methoxy, hydroxyl, α-β-unsaturated carbonyl moiety or diketone groups. Curcumin may disrupt disulfide bond formation by the electrophilic dienone. Free thiols on cysteine-rich proteins are available to react with Michael acceptors of curcumin.2
Frequently, low doses of toxins and other stressors not only are harmless but also activate an adaptive stress response that raise the resistance of the organism against high doses of the same agent.3 This phenomenon is referred to as hormesis. Many molecules that cause cell death also elicit autophagy, a cytoprotective mechanism relying on the digestion of potentially harmful intracellular structures, notably mitochondria. When higher doses of these agents are employed, cells undergo mitochondrial outer membrane permeabilization and die.
Driven by the recent literature on hormetic phytochemicals, we focused our attention on curcumin, which is known to mediate beneficial effects on health even for a better understanding of its cellular internalization, intracellular localization and mode of action. A plethora of publications proved that curcumin can bind and/or inhibit numerous targets including, for example, Nrf2, β-catenin, NF-κB, inducible nitric oxide synthase, nitric oxide, amyloid plaques, reactive oxygen species (ROS), cyclin D1, glutathione, cytosolic phospholipase A2, inhibitor of NF-κB kinase-1-2, P38MAPK, p-Tau (p-τ) and tumor necrosis factor-α. Curcumin inhibit tumor cell growth and suppress cellular entry of viruses very potently,4 and is efficient in suppressing phorbol-ester-induced tumor promotion.5 Curcumin insertion into intracellular membranes affects membrane mobility and permeability, also acting on ion channels and transporters. But the main characteristics of curcumin, justifying its hormesis capability, is to possess both antioxidant and pro-oxidant properties that are closely related to autophagic and cell death activation processes.
In a recent article published in Cell Death Discovery, Moustapha et al.6 have depicted the molecular circuitries that link curcumin to cellular stress and death, and how these pathways can get uncoupled during hormetic responses. We report that curcumin at very low doses (≤1 μM) is indeed an excellent antioxidant but that medium doses of curcumin (in the range of 5–10 μM) operates primarily as an autophagy inducer, correlating with their described capacity to reduce the acetylation of cytoplasmic proteins7 and cell cycle blocker. Finally, at further higher doses (over 25 μM), cell death is induced (all experiments run for 48 h). We investigated mechanistic aspects of the destabilization of the endoplasmic reticulum (ER) and lysosome involved in mitochondrially associated apoptosis. Curcumin induces an ER stress causing calcium release which in turn destabilizes the mitochondrial compartment to induce apoptosis. These events are also associated with lysosomal membrane permeabilization and activation of caspase-8, mediated by activation of cathepsins and calpains. This complex interplay is of huge interest, as the efficient autophagy may allow cells to escape the G2/M blockage6, 8 induced by curcumin when used at 10 μM.
It has been suggested that it may be possible to exploit autophagy for cancer therapy. After treatment of Huh7 cells with curcumin, a complex interplay involving early autophagy is induced as soon as mitochondria produce superoxide anions and hydrogen peroxide. Induction of autophagy, marked by the formation of autophagic vacuoles,6 was followed by staining with acridine orange and monodansylcadaverine dye after exposure to 10 μM curcumin. At this concentration only early events of apoptosis are detectable. Western blotting following curcumin treatment showed the conversion of LC3-I to LC3-II, a marker of active autophagosome formation. We also found that the production of ROS and formation of autophagic vacuoles following curcumin treatment was almost completely blocked by each of N-acetylcystein, the mitochondrial-targeted antioxidants, MitoQ or SKQ1, the calcium chelator, BAPTA-AM, and the mitochondrial calcium uniport inhibitor, ruthenium red (Figure 1).
Our recent findings describe the mechanism through which curcumin promotes selective tumor cell death, providing unequivocal evidence of the role of the ER and lysosomal destabilization together with an intricated cross-talk between autophagy and cell death in contrasting the proliferation of a human hepatocellular carcinoma cell line (Huh7 cells). These results fit well with the fact that other mechanistic investigations revealed that curcumin treatment also upregulated the ER stress markers CHOP and Bip/GRP78 (ref. 9) and, as we described, the autophagic marker LC3-II. In addition, curcumin induced ER stress by triggering ROS generation, which was supported by the finding that treating cells with the antioxidant N-acetylcystein alleviated curcumin-mediated ER stress and vacuolation-mediated death.
Autophagy, a lysosomal degradation pathway for cellular constituents and organelles, is an adaptive and essential process required for cellular homeostasis. Although autophagy can also lead to a non-apoptotic form of programmed cell death called autophagy-induced cell death or autophagy-associated cell death. Thus, with these results,6 we are entering straight in the main ongoing discussions about the curcumin capability to induce autophagic processes and to evaluate its potency. Either being a complete autophagy with autophagolysosome formation or an intense vacuolization with no fusion with the lysomomes and ceramide accumulation.10
All these recent findings suggest that curcumin or curcumin derivatives have the potential to be developed into pro-autophagic drugs for the treatment of cancers1, 11 and malignant gliomas.10 Various formulations of curcumin, including nanoparticles, liposomal encapsulation, emulsions, capsules, tablets and powder, have been examined. The capacity of these compounds to provide a means of cancer cell death that enhances the effects of standard therapies should be taken into consideration for designing novel therapeutic strategies. Moreover, and alternatively, the regulation of autophagy by polyphenolic coumpounds12 if controlled should be considered as a potential therapeutic strategy for cancer.1
The authors declare no conflict of interest.
References
- 1Gupta SC et al. AAPS J 2013; 15: 195–218. [DOI] [PMC free article] [PubMed]
- 2Prasad S et al. Biotechnol Adv 2014; 32; 1053–1064. [DOI] [PubMed]
- 3Davis JM et al. J Toxicol Environ Health 1990; 30: 71–83. [DOI] [PubMed]
- 4Moghadamtousi SZ et al. Biomed Res Int 2014; 2014: 186864. [DOI] [PMC free article] [PubMed]
- 5Han SS et al. J Biochem Mol Biol 2002; 35: 337–342. [DOI] [PubMed]
- 6Moustapha A et al. Cell Death Discovery 2015; 1: 15017. [DOI] [PMC free article] [PubMed]
- 7Pietrocola F et al. Cell Cycle 2012; 11: 3851–3860. [DOI] [PMC free article] [PubMed]
- 8Zhang X et al. Front Physiol 2014; 5: 94. [DOI] [PMC free article] [PubMed]
- 9Lee WJ et al. Sci Rep 2015; 5: 10420.26013662
- 10Thayyullathil F et al. FEBS Open Bio 2014; 4: 763–776.
- 11Zhou T et al. PLoS One 2014; 9: e107876. [DOI] [PMC free article] [PubMed]
- 12Hasima N et al. Cell Death Dis 2014; 5: e1509. [DOI] [PMC free article] [PubMed]